Overview

SINGLE DOSE CROSSOVER COMPARATIVE BIOAVAILABILITY STUDY OF BUPROPION HCl MR TABLET 300 MG

Status:
Completed
Trial end date:
2020-02-05
Target enrollment:
Participant gender:
Summary
The objective of this study is to determine the bioequivalence of 2 different formulations of bupropion after a single oral dose administration under fasting conditions. The secondary objective of this study is to evaluate the safety and tolerability of the Test and Reference formulations in healthy subjects.
Phase:
Phase 1
Details
Lead Sponsor:
Alembic Pharmaceuticals Ltd.
Treatments:
Bupropion